共 50 条
- [21] A randomized, double-blind, placebo-controlled study of ustekinumab in Chinese patients with moderate to severe plaque psoriasis: LOTUS trial resultsJOURNAL OF DERMATOLOGY, 2012, 39 : 238 - 239Zheng MinZhu Xue-junSong, MichaelYaung-Kaung ShenWang Bao-xi
- [22] A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisBRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (02) : 273 - 286Papp, K. A.Reich, K.Paul, C.Blauvelt, A.Baran, W.Bolduc, C.Toth, D.Langley, R. G.Cather, J.Gottlieb, A. B.Thaci, D.Krueger, J. G.Russell, C. B.Milmont, C. E.Li, J.Klekotka, P. A.Kricorian, G.Nirula, A.
- [23] Two phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety resultsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB66 - AB66Papp, Kim A.Menter, Martin A.Abe, MasatoshiElewski, Boni E.Feldman, Steven R.Gottlieb, Alice G.Thaci, DiamantLuger, ThomasTatulych, SvitlanaGupta, PankajProulx, JamesLan, Shu-PingWolk, Robert
- [24] Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanerceptJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (01) : 86 - 92Bagel, JerryLynde, CharlesTyring, StephenKricorian, GregoryShi, YifeiKlekotka, Paul
- [25] A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasisBRITISH JOURNAL OF DERMATOLOGY, 2024, 191 (03) : 336 - 343Cai, LinJiang, CongjunZhang, GuoqiangFang, HongWang, JinyanLi, YumeiXu, HuiXiao, RongDing, YangfengHuang, KunZhang, ChunleiZhang, LitaoChen, BinDuan, XinsuoPan, WeiliHan, GuangmingChen, RongyiLiu, LunfeiZhang, ShouminTao, JuanPang, XiaowenYu, JianbinWang, HuipingZhao, YiLi, ChengxinKang, XiaojingQin, LanyingZhu, XiaofangSu, JuanLi, ShanshanYang, ChunjunFeng, WenliLei, TiechiJiang, ShanFang, RuihuaLin, MaoLu, QianjinXu, ChunxingWang, WeiZhang, Jianzhong
- [26] Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b studyJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (01) : 91 - 99Gebauer, KurtSpelman, LyndaYamauchi, Paul S.Bagel, JerryNishandar, TusharCrane, MichaelKopeloff, IrisKothekar, MudgalYao, Siu-LongSofen, Howard L.
- [27] Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded studyJOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1392 - 1403Youn, Sang WoongJo, Seong JinPark, Chul JongKim, Dong HyunShin, Bong SeokJeong, Ki HeonBang, Chul HwanCross, NancyThirlwell, JackieHoepken, Bengt
- [28] A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisBRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) : 649 - 657Gottlieb, A. B.Langley, R. G.Strober, B. E.Papp, K. A.Klekotka, P.Creamer, K.Thompson, E. H. Z.Hooper, M.Kricorian, G.
- [29] Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet Efficacy and Safety Results From REACH, a Randomized, Placebo-Controlled, Double-blind TrialARCHIVES OF DERMATOLOGY, 2011, 147 (04) : 429 - 436Leonardi, CraigLangley, Richard G.Papp, KimTyring, Stephen K.Wasel, NormanVender, RonaldUnnebrink, KristinaGupta, Shiraz R.Valdecantos, Wendell C.Bagel, Jerry
- [30] Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyBRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) : 412 - 421Papp, K. A.Langley, R. G.Sigurgeirsson, B.Abe, M.Baker, D. R.Konno, P.Haemmerle, S.Thurston, H. J.Papavassilis, C.Richards, H. B.